Research conducted by MAPS on MDMA-Assisted Psychotherapy for PTSD is granted Breakthrough Therapy designation by the FDA. The FDA approves the MAPS protocol for Phase 3 clinical trials.

Resource: Multidisciplinary Association for Psychedelic Studies

Leave a comment